Table 3.
Clinical and laboratory features of 97 MPNs patients stratified by TET2 status.
| TET2-positive MPN (n = 7) | TET2-negative MPN (n = 90) | P value | |
|---|---|---|---|
| Diagnosis | |||
| MPN-U (n = 8) | 3 (37.5%) | 5/8 (62.5%) | |
| ET (n = 55) | 2 (3.6%) | 53 (96.4%) | 0.005 |
| PV (n = 25) | 2 (8.0%) | 23 (92%) | |
| IMF (n = 9) | 0 | 9 | |
| Median age, years (range) | 71 (43–76) | 65.5 (25–89) | 0.57 |
| Follow-up months, median (range) | 38.6 (13.3–130) | 54.2 (4.3–195.7) | 0.38 |
| Hb, g/100 mL (range) | 16.1 (13.3–19.9) | 15.2 (11.1–21.5) | 0.22 |
| WBC × 109/L (range) | 6.86 (5.4–12.4) | 8.56 (1.7–19.6) | 0.3 |
| Monocytes × 109/L (range) | 0.3 (0.1–1.15) | 0.45 (0.02–0.9) | 0.45 |
| Plt × 109/L (range) | 476 (134–849) | 629 (149–1750) | 0.02 |
| JAK 2 V617F n (%) | 6/7 (85.7) | 66/90 (73.3) | 0.78 |
| JAK 2 V617F burden median % (range) | 24 (5–65) | 25 (5–90) | 0.99 |
| EEC n (%) | 4/7 (57.1) | 71/90 (78.8) | 0.39 |
| CFU-MK n (%) | 1/7 (14.2) | 57/90 (63.3) | 0.01 |
| CD34 + SP × 109/L (range) | 0.021 (0.0103–0.273) | 0.03 (0.0015–0.61) | 0.89 |
| CD34 + SP (%) (range) | 0.03 (0.02–0.35) | 0.035 (0.0015–0.56) | 0.43 |
| Bone marrow cellularity % (range) | 50 (30–80) | 50 (20–98) | 0.96 |
| Single cytogenetic abnormality (n) | 0/7 | 5/90 (5.5) | 0.49 |
| Complex karyotype (n) | 0/7 | 1/90 (1.1) | |
| Trisomy (n) | 0/7 | 1/90 (1.1) | |
| Pruritus (n) | 2/7 | 21/90 | 0.88 |
| Palpable splenomegaly (n) | 2/7 | 37/90 | 0.8 |
| Splenic square cm2 (range) | 40 (31–105) | 42 (25–200) | 0.45 |
| Arterial thromboses (n) | 1/7 | 21/90 | 0.43 |
| Venous thromboses (n) | 2/7 | 7/90 | |
| Spontaneous haemorrhage (n) | 0/7 | 2/90 | 0.58 |
| Posttraumatic haemorrhage (n) | 0/7 | 2/90 | |
| Cytoreductive treatment (n) | 7/7 | 86/90 | 0.66 |